Susquehanna International Group, LLP Protalix Bio Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $560 Billion
- Q3 2024
A detailed history of Susquehanna International Group, LLP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 70,817 shares of PLX stock, worth $129,595. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,817
Previous 158,247
55.25%
Holding current value
$129,595
Previous $185,000
61.08%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding PLX
# of Institutions
50Shares Held
3.58MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$1.75 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$796,4390.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$683,9750.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$609,7020.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$494,1000.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $91M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...